EX-4.9



 Exhibit 4.9 

NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR
DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE ACT OR RECEIPT OF A NO-ACTION LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
 WARRANT TO
PURCHASE 43,140 SHARES OF COMMON STOCK 
 December 11, 1997 

THIS CERTIFIES THAT, for value received, Lease Management Services, Inc., (“Holder”) is entitled to subscribe for and purchase 43,140 shares of the
fully paid and nonassessable Common Stock (“the Shares”) of FIBROGEN, INC., a Delaware corporation (the “Company”), at the Warrant Price (as hereinafter defined), subject to the provisions and upon the terms and conditions
hereinafter set forth. As used herein, the term “Common Stock” shall mean the Company’s presently authorized Common Stock, and any stock into which such Common Stock may hereafter be exchanged. 

1.    Warrant Price. The Warrant Price shall initially be One and 75/100 dollars ($1.75) per share, subject to adjustment as
provided in Section 7 below. 
 2.    Conditions to Exercise. The purchase right represented by this Warrant may be
exercised at any time, or from time to time, in whole or in part during the term commencing on the date hereof and ending on the earlier of: 

(a)    5:00 P.M. Pacific time on the 6th annual anniversary of this Warrant; or 

(b)    the closing of the initial public offering of the Company’s Common Stock pursuant to a registration statement
under the Securities Act of 1933, as amended (the “Initial Public Offering”). The Company shall provide notice of the Initial Public Offering to the Holder at least 30 days prior to the closing thereof; or 

(c)    the effective date of the merger of the Company with or into, the consolidation of the Company with, or the sale by
the Company of all or substantially all of its assets to another corporation or other entity (other than such a transaction wherein the shareholders of the Company retain or obtain a majority of the voting capital stock of the surviving, resulting,
or purchasing corporation); provided that the Company shall notify the registered Holder of this Warrant of the proposed effective date of the merger, consolidation, or sale at least 30 days prior to the effectiveness thereof. 

In the event that, although the Company shall have given notice of a transaction pursuant to subparagraph (b) or subparagraph
(c) hereof, the transaction does not close within 60 days of the day specified by the Company, unless otherwise elected by the Holder any exercise of the Warrant subsequent to the giving of such notice shall be rescinded and the Warrant shall
again be exercisable until terminated in accordance with this Paragraph 2. 

  
 1. 








 LMSI/ FIBROGEN, INC. WARRANT 

Page 2 of 7 
 3.    Method of Exercise;
Payment; Issuance of Shares; Issuance of New Warrant. 
 (a)    Cash Exercise. Subject to Section 2 hereof, the purchase
right represented by this Warrant may be exercised by the Holder hereof, in whole or in part, by the surrender of this Warrant (with a duly executed Notice of Exercise in the form attached hereto) at the principal office of the Company (as set forth
in Section 18 below) and by payment to the Company, by check, of an amount equal to the then applicable Warrant Price per share multiplied by the number of shares then being purchased. In the event of any exercise of the rights represented by
this Warrant, certificates for the shares of stock so purchased shall be in the name of, and delivered to, the Holder hereof, or as such Holder may direct (subject to the terms of transfer contained herein and upon payment by such Holder hereof of
any applicable transfer taxes). Such delivery shall be made within 30 days after exercise of the Warrant and at the Company’s expense and, unless this Warrant has been fully exercised or expired, a new Warrant having terms and conditions
substantially identical to this Warrant and representing the portion of the Shares, if any, with respect to which this Warrant shall not have been exercised, shall also be issued to the Holder hereof within 30 days after exercise of the Warrant.

 (b)    Net Issue Exercise. In lieu of exercising this Warrant pursuant to Section 3(a), Holder may elect to receive
shares equal to the value of this Warrant (or of any portion thereof remaining unexercised) by surrender of this Warrant at the principal office of the Company together with notice of such election, in which event the Company shall issue to Holder
the number of shares of the Company’s Common Stock computed using the following formula: 
 X = Y (A-B)  

A 
 Where X = the number of
shares of Common Stock to be issued to Holder. 
 Y = the number of shares of Common Stock purchasable under this Warrant (at the date of
such calculation). 
 A = the Fair Market Value of one share of the Company’s Common Stock (at the date of such calculation). 

B = Warrant Price (as adjusted to the date of such calculation). 

(c)    Fair Market Value. For purposes of this Section 3, Fair Market Value of one share of the Company’s Common Stock
shall mean: 
 (i)    In the event of an exercise in connection with an Initial Public Offering, the per share Fair
Market Value for the Common Stock shall be the Offering Price at which the underwriters initially sell Common Stock to the public; or 

(ii)    The average of the closing bid and asked prices of the Common Stock quoted in the Over-The-Counter Market Summary,
or the average of the last reported sale price of the Common Stock or the closing price quoted on the Nasdaq National Market System (“NMS”) or on any exchange on which the Common Stock is listed, whichever is applicable, as published in
the Western Edition of the Wall Street Journal over the ten (10) trading days prior to the date of determination of fair market value; or 

(iii)    In the event of an exercise in connection with a merger, acquisition or other consolidation in which the Company
is not the surviving entity, as described in Section 2(c), the per share Fair Market Value for the Common Stock shall be the value to be 

  
 2. 








 LMSI/ FIBROGEN, INC. WARRANT 

Page 3 of 7 
 received per share of Common Stock
by all holders of the Common Stock in such transaction as determined by the Board of Directors; or 
 (iv)    If the
Common Stock is not publicly traded, the per share fair market value of the Common Stock shall be as determined in good faith by the Company’s Board of Directors. 

In the event of 3(c)(iii) or 3(c)(iv), above, the Company’s Board of Directors shall prepare a certificate, to be signed by an authorized
Officer of the Company, setting forth in reasonable detail the basis for and method of determination of the per share Fair Market Value of the Common Stock. The Board will also certify to the Holder that this per share Fair Market Value will be
applicable to all holders of the Company’s Common Stock. Such certification must be made to Holder at least thirty (30) business days prior to the proposed effective date of the merger, consolidation, sale, or other triggering event as defined
in 3(c)(iii) and 3(c)(iv). 
 (d)    Automatic Exercise. To the extent this Warrant is not previously exercised, it shall be
automatically exercised in accordance with Sections 3(6) and 3(c) hereof (even if not surrendered) immediately before: (i) its expiration, or (ii) the closing of an Initial Public Offering pursuant to Section 2(b), or (iii) the
consummation of any consolidation or merger of the Company, or any sale or transfer of a majority of the Company’s assets pursuant to Section 2(c). 

4.    Representations and Warranties of Holder and Restrictions on Transfer Imposed by the Securities Act of 1933. 

(a)    Representations and Warranties by Holder. The Holder represents and warrants to the Company with respect to this purchase as
follows: 
 (i)    The Holder has substantial experience in evaluating and investing in private placement transactions of
securities of companies similar to the Company so that the Holder is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its interests. 

(ii)    The Holder is acquiring the Warrant and the Shares of Common Stock issuable upon exercise of the Warrant
(collectively the “Securities”) for investment for its own account and not with a view to, or for resale in connection with, any distribution thereof. The Holder understands that the Securities have not been registered under the Securities
Act of 1933, as amended (the “Act”) by reason of a specific exemption from the registration provisions of the Act which depends upon, among other things, the bona fide nature of the investment intent as expressed herein. In this
connection, the Holder understands that, in the view of the Securities and Exchange Commission (the “SEC”), the statutory basis for such exemption may be unavailable if this representation was predicated solely upon a present intention to
hold the Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities or for a period of one year or any other fixed period in the
future. 
 (iii)    The Holder acknowledges that the Securities must be held indefinitely unless subsequently registered
under the Act or an exemption from such registration is available. The Holder is aware of the provisions of Rule 144 promulgated under the Act (“Rule 144”) which permits limited resale of securities purchased in a private placement subject
to the satisfaction of certain conditions, including, in case the securities have been held for less than two years, the existence of a public market for the shares, the availability of certain public information about the Company, the resale
occurring not less than one year 

  
 3. 








 LMSI/ FIBROGEN, INC. WARRANT 

Page 4 of 7 
 after a party has purchased and paid
for the security to be sold, the sale being through a “broker’s transaction” or in a transaction directly with a “market maker” (as provided by Rule 144(f)) and the number of shares or other securities being sold during any
three-month period not exceeding specified limitations. 
 (iv)    The Holder further understands that at the time the
Holder wishes to sell the Securities there may be no public market upon which such a sale may be effected, and that even if such a public market exists, the Company may not be satisfying the current public information requirements of Rule 144, and
that in such event, the Holder may be precluded from selling the Securities under Rule 144 unless a) a two-year minimum holding period has been satisfied and b) the Holder was not at the time of the sale nor at any time during the three-month period
prior to such sale an affiliate of the Company. 
 (v)    The Holder has had an opportunity to discuss the Company’s
business, management and financial affairs with its management and an opportunity to review the Company’s facilities. The Holder understands that such discussions, as well as the written information issued by the Company, were intended to
describe the aspects of the Company’s business and prospects which it believes to be material but were not necessarily a thorough or exhaustive description. 

(b)    Legends. Each certificate representing the Securities shall be endorsed with the following legend: 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE TRANSFERRED UNLESS COVERED BY AN EFFECTIVE
REGISTRATION STATEMENT UNDER SAID ACT, A “NO ACTION” LETTER FROM THE SECURITIES AND EXCHANGE COMMISSION WITH RESPECT TO SUCH TRANSFER, A TRANSFER MEETING THE REQUIREMENTS OF RULE 144 OF THE SECURITIES AND EXCHANGE COMMISSION, OR AN OPINION
OF COUNSEL SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY SUCH TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 The Company need not enter into its stock
record a transfer of Securities unless the conditions specified in the foregoing legend are satisfied. The Company may also instruct its transfer agent not to allow the transfer of any of the Shares unless the conditions specified in the foregoing
legend are satisfied. 
 (c)    Removal of Legend and Transfer Restrictions. The legend relating to the Act endorsed on a
certificate pursuant to paragraph 4(b) of this Warrant and the stop transfer instructions with respect to the Securities represented by such certificate shall be removed and the Company shall issue a certificate without such legend to the
Holder of the Securities if (i) the Securities are registered under the Act and a prospectus meeting the requirements of Section 10 of the Act is available or (ii) the Holder provides to the Company an opinion of counsel for the
Holder reasonably satisfactory to the Company, or a no-action letter or interpretive opinion of the staff of the SEC reasonably satisfactory to the Company, to the effect that public sale, transfer or assignment of the Securities may be made without
registration and without compliance with any restriction such as Rule 144. 
 5.    Condition of Transfer or Exercise of Warrant.
It shall be a condition to any transfer or exercise of this Warrant that at the time of such transfer or exercise, the Holder shall provide the Company with a representation in writing that the Holder or transferee is acquiring this Warrant and the
shares of Common Stock to be issued upon exercise for investment purposes only and 

  
 4. 








 LMSI/ FIBROGEN, INC. WARRANT 

Page 5 of 7 
 not with a view to any sale or distribution, or will
provide the Company with a statement of pertinent facts covering any proposed distribution. As a further condition to any transfer of this Warrant or any or all of the shares of Common Stock issuable upon exercise of this Warrant, other than a
transfer registered under the Act, the Company must have received a legal opinion, in form and substance satisfactory to the Company and its counsel, reciting the pertinent circumstances surrounding the proposed transfer and stating that such
transfer is exempt from the registration and prospectus delivery requirements of the Act. Each certificate evidencing the shares issued upon exercise of the Warrant or upon any transfer of the shares (other than a transfer registered under the Act
or any subsequent transfer of shares so registered) shall, at the Company’s option, contain a legend in form and substance satisfactory to the Company and its counsel, restricting the transfer of the shares to sales or other dispositions exempt
from the requirements of the Act. 
 As further condition to each transfer, the Holder shall surrender this Warrant to the Company and the
transferee shall receive and accept a Warrant, of like tenor and date, executed by the Company. 
 6.    Stock Fully Paid;
Reservation of Shares. All Shares which may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be fully paid and nonassessable, and free from all taxes, liens, and charges with respect to the issue
thereof. During the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for issuance upon exercise of the purchase rights evidenced by this Warrant, a sufficient
number of shares of its Common Stock to provide for the exercise of the rights represented by this Warrant. 
 7.    Adjustment for
Certain Events. In the event of changes in the outstanding Common Stock by reason of stock dividends, split-ups, recapitalizations, reclassifications, mergers, consolidations, combinations or exchanges of shares, separations, reorganizations,
liquidations, or the like, the number and class of shares available under the Warrant in the aggregate and the Warrant Price shall be correspondingly adjusted, as appropriate, by the Board of Directors of the Company. The adjustment shall be such as
will give the Holder of this Warrant upon exercise for the same aggregate Warrant Price the total number, class and kind of shares as he would have owned had the Warrant been exercised prior to the event and had he continued to hold such shares
until after the event requiring adjustment. 
 8.    Notice of Adjustments. Whenever any Warrant Price shall be adjusted pursuant
to Section 7 hereof, the Company shall prepare a certificate signed by an officer of the Company setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was
calculated, and the Warrant Price and number of shares issuable upon exercise of the Warrant after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (by certified or registered mail, return receipt required,
postage prepaid) within thirty (30) days of such adjustment to the Holder of this Warrant as set forth in Section 18 hereof. 

9.    “Market Stand-Off” Agreement. Holder hereby agrees that for a period of up to 180 days following the effective date
of the first registration statement of the Company covering common stock (or other securities) to be sold on behalf of the Company in an underwritten public offering, it will not, to the extent requested by the Company and any underwriter, sell or
otherwise transfer or dispose of (other than to donees or transferees who agree to be similarly bound) any of the Shares at any time during such period except common stock included in such registration; provided, however, that all officers and
directors of the Company who hold 

  
 5. 








 LMSI/ FIBROGEN, INC. WARRANT 

Page 6 of 7 
 securities of the Company or options to acquire
securities of the Company and all other persons with registration rights enter into similar agreements. 
 10.    Transferability of
Warrant. This Warrant is transferable on the books of the Company at its principal office by the registered Holder hereof upon surrender of this Warrant properly endorsed, subject to compliance with Section 5 and applicable federal and
state securities laws. The Company shall issue and deliver to the transferee a new Warrant representing the Warrant so transferred. Upon any partial transfer, the Company will issue and deliver to Holder a new Warrant with respect to the Warrant not
so transferred. Holder shall not have any right to transfer any portion of this Warrant to any direct competitor of the Company. 

11.    No Fractional Shares. No fractional share of Common Stock will be issued in connection with any exercise hereunder, but in
lieu of such fractional share the Company shall make a cash payment therefor upon the basis of the Warrant Price then in effect. 

12.    Charges, Taxes and Expenses. Issuance of certificates for shares of Common Stock upon the exercise of this Warrant shall be
made without charge to the Holder for any United States or state of the United States documentary stamp tax or other incidental expense with respect to the issuance of such certificate, all of which taxes and expenses shall be paid by the Company,
and such certificates shall be issued in the name of the Holder. 
 13.    No Shareholder Rights Until Exercise. This Warrant
does not entitle the Holder hereof to any voting rights or other rights as a shareholder of the Company prior to the exercise hereof. 

14.    Registry of Warrant. The Company shall maintain a registry showing the name and address of the registered Holder of this
Warrant. This Warrant may be surrendered for exchange or exercise, in accordance with its terms, at such office or agency of the Company, and the Company and Holder shall be entitled to rely in all respects, prior to written notice to the contrary,
upon such registry. 
 15.    Loss, Theft, Destruction or Mutilation of Warrant. Upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft, or destruction, of indemnity reasonably satisfactory to it, and, if mutilated, upon surrender and cancellation of this
Warrant, the Company will execute and deliver a new Warrant, having terms and conditions substantially identical to this Warrant, in lieu hereof. 

16.    Miscellaneous. 

(a)    Issue Date. The provisions of this Warrant shall be construed and shall be given effect in all respect as if
it had been issued and delivered by the Company on the date hereof. 
 (b)    Successors. This Warrant shall be
binding upon any successors or assigns of the Company. 
 (c)    Governing Law. This Warrant shall be governed by
and construed in accordance with the laws of the State of California. 
 (d)    Headings. The headings used in
this Warrant are used for convenience only and are not to be considered in construing or interpreting this Warrant. 

  
 6. 








 LMSI/ FIBROGEN, INC. WARRANT 

Page 7 of 7 

(e)    Saturdays, Sundays, Holidays. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday in the State of California, then such action may be taken or such right may be exercised on the next succeeding day not a legal holiday. 

17.    No Impairment. The Company will not, by amendment of its Certificate of Incorporation or any other voluntary action, avoid
or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to
protect the rights of the Holder hereof against impairment. 
 18.    Addresses. Any notice required or permitted hereunder shall
be in writing and shall be mailed by overnight courier, registered or certified mail, return receipt required, and postage pre-paid, or otherwise delivered by hand or by messenger, addressed as set forth below, or at such other address as the
Company or the Holder hereof shall have furnished to the other party. 
 If to the
Company:                                        
FIBROGEN, INC. 

                     
                                         
        260 Littlefield Avenue 

                     
                                         
        South San Francisco, CA 94080 

                     
                                         
        Attn:    Thomas Neff, CEO 

                     
                                         
        After February 1, 1998: 

                     
                                         
        225 Gateway Blvd. 

                     
                                         
        South San Francisco, CA 94080 
 If to the
Holder:                                        
    Lease Management Services, Inc. 

                     
                                         
        2500 Sand Hill Road, Suite 101 

                     
                                         
        Menlo Park, CA 94025 

                     
                                         
        Attn:    Barbara B. Kaiser, EVP/GM 
 IN WITNESS WHEREOF, FIBROGEN, INC. has caused this
Warrant to be executed by its officers thereunto duly authorized. 
 Dated as of Dec 11, 1997. 

 

			
	     /s/ Thomas Neff

		
	 BY:
	 	     Thomas
Neff



 
			
		
	 TITLE:
	 	     CEO




  
 7. 








 NOTICE OF EXERCISE 

TO: 
  

	1.	The undersigned Warrantholder (“Holder”) elects to acquire shares of the Common Stock of FIBROGEN, INC. (the “Company”), pursuant to the terms of the Stock Purchase Warrant dated
                    , 1997, (the “Warrant”). 

  


	2.	The Holder exercises its rights under the Warrant as set forth below: 

  

					
		 	 (            )
	 	 The Holder elects to purchase              shares of Common Stock as provided in
Section 3(a), (c) and tenders herewith a check in the amount of $             as payment of the purchase price.

			
		 	 (            )
	 	 The Holder elects to convert the purchase rights into shares of Common Stock as provided in Section 3(b), (c) of the Warrant.


  

	3.	The Holder surrenders the Warrant with this Notice of Exercise. 

  

	4.	The Holder represents that it is acquiring the aforesaid shares of Common Stock for investment and not with a view to, or for resale in connection with, distribution and that the Holder has no present intention of
distributing or reselling the shares. 

  

	5.	Please issue a certificate representing the shares of Common Stock in the name of the Holder or in such other name as is specified below: 


Name: 
 Address: 

Taxpayer I.D.: 
  

			
	  
 (Holder)

		
	By:	 	  

		
	Title:	 	  

		
	Date:	 	  










 AMENDMENT TO WARRANT TO PURCHASE 

43,140 SHARES 
 OF COMMON STOCK 

WHEREAS; General Electric Capital Corporation as successor in interest to Lease Management Services, Inc. (the “Holder” or the
“Secured Party”) is the holder of that certain Warrant, dated December 11,1997, to purchase Forty Three Thousand One Hundred Forty (43,140) shares of fully paid and non-assessable Common Stock of FibroGen, Inc. (the
“Company”) (the “Warrant”); 
 WHEREAS; The Company and the Holder wish to amend the Warrant to provide that it may be
exercisable until the date one year after effectiveness of the Company’s initial public offering; 
 NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and in consideration of the mutual promises contained herein, the parties hereto agree as follows: 

Section 2(a) of the Warrant is hereby amended to read as follows: 
  

	 	(a)	at 5:00 P.M. P.S.T on the date one year after the effectiveness of the Company’s Initial Public Offering; or 


Capitalized terms not defined herein shall have the meaning ascribed to them in the Warrant. 

 

	
	AGREED AND ACCEPTED:
	
	COMPANY
	
	   /s/ Wilbert Lee

	By:
	
	   CFO

	Title
	
	Date: December 9, 2003
	
	HOLDER
	
	   /s/ [Illegible Signature]

	By:
	
	   SVP

	Title
	
	Date: December 9, 2003